Phase II study of OPN-305, a humanised anti-TLR2 monoclonal antibody, in renal transplant patients at high risk of delayed graft function
Delayed Graft Function
Enrolment: 252 · Results not recorded
Loading the evidence…
Biologic · Toll-like receptor 2 antagonist (ANTAGONIST, direct_interaction=true, disease_efficacy=true). NOTE: ChEMBL entry is TOMARALIMAB/OPN-305, the humanised anti-TLR2 monoclonal antibody; OPN301 is the murine parent antibody used preclinically. Matched at programme level, not identical molecule.
0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Delayed Graft Function
Enrolment: 252 · Results not recorded
Myelodysplastic Syndrome
Enrolment: 96 · Results not recorded
Myelodysplastic Syndrome
Enrolment: 14 · Results not recorded
1 studies reported at therapy level; 1 evidence entries itemised.
Model: Isograft renal transplantation with 30 min of cold ischaemia
OPN301 improved graft function, with blood urea nitrogen of 19.8 plus or minus 1.9 micromolar against 33.9 plus or minus 3.2 in isotype-treated mice, preserved tubular structure and reduced C3d deposition.
Extraction: extract · Subtype source: rule · Supplied extraction confidence: 0.72. Machine-extracted fields require source verification.